Erlotinib 150mg Tablets, 30x1 Tablets Medicine Raw Materials

Erlotinib is an inhibitor of the epidermal growth factor receptor egfr tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name tarceva. Erlotinib binds to the epidermal growth factor receptor egfr tyrosine kinase in a reversible fashion at the adenosine triphosphate atp binding site of the receptor. Erlotinib at the standard oral daily dose of 150mg is approved for the treatment of unselected chemorefractory advanced non-small cell lung cancer patients as well as maintenance therapy after first-line chemotherapy. Erlotinib is a non-chemotherapy drug for the treatment of advanced or metastatic nsclc and is administered orally once a day. It successfully inhibits egfr, a protein involved in the growth and development of cancers.